Literature DB >> 1277215

Sparing effect of cyclophosphamide (NSC-26271) pretreatment on animals lethally treated with gamma-irradiation.

J L Millar, B N Hudspith.   

Abstract

Cyclophosphamide (CP) can protect mice from gamma-irradiation-induced lethality, the timing of the dose of CP in relation to the irradiation being the critical factor. The most sparing effect is achieved when CP is injected 3 days before irradiation. The protection is mediated by enhanced hemopoietic recovery seen in animals given the most favorable combination ofCP and gamma-irradiation. This rapid recovery cannot be explained by the reduced sensitivity of hemopoietic stem cells after CP treatment to subsequent irradiation although survival of a few radioresistant stem cells cannot be ruled out. Stimulus to repopulate by nonspecific depletion of the bone marrow is not the explanation either, since CP itself appears to play an important role in this effect. The role of the spleen is not critical in this phenomenon and attempts have failed to demonstrate the presence of a humoral factor which can restore bone marrow depleted by gamma-irradiation in the serum of animals treated with CP. CP given 3 days before irradiation appears to result in a purely additive effect against malignant tissue in mice, providing a useful differential kill on tumor tissue at the same time that it provides the maximum protection of normal tissue.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 1277215

Source DB:  PubMed          Journal:  Cancer Treat Rep        ISSN: 0361-5960


  10 in total

1.  Gut protection by cyclophosphamide "priming" in patients receiving high-dose melphalan--effect of drug scheduling.

Authors:  J Mansi; E Ellis; C Viner; J Mundy; T Smith; J Millar; S Milan; M Gore; D Cunningham
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

2.  Cyclophosphamide and cis-dichlorodiammine platinum (11). Nonempiric scheduling to spare dose-limiting tissues in the rat.

Authors:  K D Tew; D M Taylor
Journal:  Cancer Chemother Pharmacol       Date:  1980       Impact factor: 3.333

Review 3.  [Hematopoietic stimulation for enhanced bone marrow regeneration after chemotherapy (author's transl)].

Authors:  L Labedzki; D Noack
Journal:  Klin Wochenschr       Date:  1980-03-03

Review 4.  The impact of redox and thiol status on the bone marrow: Pharmacological intervention strategies.

Authors:  Christina L Grek; Danyelle M Townsend; Kenneth D Tew
Journal:  Pharmacol Ther       Date:  2010-10-15       Impact factor: 12.310

5.  The binding of [3H]-oestradiol-17 beta in the immature rat uterus during the sequential administration of non-steroidal anti-oestrogens.

Authors:  V C Jordan; K E Naylor
Journal:  Br J Pharmacol       Date:  1979-02       Impact factor: 8.739

6.  Sequence-dependent toxicity and small bowel mucosal injury in neonatal mice treated with low doses of 5-azacytidine and X-irradiation at the late organogenesis stage.

Authors:  W Schmahl
Journal:  Radiat Environ Biophys       Date:  1983       Impact factor: 1.925

7.  Priming with low doses of methyl-CCNU reduce the toxicity of high doses of methyl-CCNU and melphalan, and increase the lifespan of mice implanted with Lewis lung carcinoma.

Authors:  A Zimber; K Perk; I Livnat
Journal:  Br J Cancer       Date:  1988-03       Impact factor: 7.640

8.  Effect of high-dose melphalan on marrow and intestinal epithelium in mice pretreated with cyclophosphamide.

Authors:  J L Millar; B N Hudspith; T J McElwain; T A Phelps
Journal:  Br J Cancer       Date:  1978-07       Impact factor: 7.640

9.  Treatment of advanced neuroblastoma: feasibility and therapeutic potential of a novel approach combining 131-I-MIBG and multiple drug chemotherapy.

Authors:  S Mastrangelo; A Tornesello; L Diociaiuti; A Pession; A Prete; V Rufini; L Troncone; R Mastrangelo
Journal:  Br J Cancer       Date:  2001-02       Impact factor: 7.640

10.  Cyclophosphamide-induced lung damage in mice: protection by a small preliminary dose.

Authors:  C H Collis; C M Wilson; J M Jones
Journal:  Br J Cancer       Date:  1980-06       Impact factor: 7.640

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.